TG Therapeutics, Inc. (Nasdaq: TGTX) announced upcoming presentations of clinical data for TG-1101, the Company's next generation, glycoengineered anti-CD20 monoclonal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE